Guest edited by Professor Rhian Touyz and Dr Ninian Lang
The last few years have seen dramatic improvements in cancer survival, in large part because of the rapid development of an expanding range of novel anti-cancer therapies. However, a number of these modern anti-cancer drugs have unwanted cardiovascular effects. The potential for cardiovascular toxicity associated with these drugs often reflects overlap between pathogenic cancer mechanisms and physiological pathways required for normal cardiovascular function. Clinical Science has, therefore, compiled a themed collection to reflect the growing relevance of Cardiovascular-Oncology as a specialty that aims to refine our understanding and management of these competing risks. This collection brings together reviews and original research articles examining the intersection between cancer treatments and their potentially harmful cardiovascular effects as well as addressing the cardiovascular effects of malignancy per se.
We would like to thank the all of the authors for their excellent contributions and announce that this collection will remain open for research submissions. You can submit your research on our website or contact email@example.com for more information.
Collection image featured in 10.1042/CS20200308.